全文获取类型
收费全文 | 4253篇 |
免费 | 336篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 71篇 |
儿科学 | 122篇 |
妇产科学 | 74篇 |
基础医学 | 512篇 |
口腔科学 | 95篇 |
临床医学 | 355篇 |
内科学 | 786篇 |
皮肤病学 | 48篇 |
神经病学 | 368篇 |
特种医学 | 524篇 |
外科学 | 499篇 |
综合类 | 153篇 |
一般理论 | 1篇 |
预防医学 | 425篇 |
眼科学 | 73篇 |
药学 | 166篇 |
1篇 | |
中国医学 | 1篇 |
肿瘤学 | 321篇 |
出版年
2021年 | 45篇 |
2020年 | 33篇 |
2019年 | 61篇 |
2018年 | 68篇 |
2017年 | 52篇 |
2016年 | 61篇 |
2015年 | 59篇 |
2014年 | 102篇 |
2013年 | 156篇 |
2012年 | 199篇 |
2011年 | 187篇 |
2010年 | 138篇 |
2009年 | 136篇 |
2008年 | 164篇 |
2007年 | 191篇 |
2006年 | 179篇 |
2005年 | 156篇 |
2004年 | 162篇 |
2003年 | 143篇 |
2002年 | 139篇 |
2001年 | 132篇 |
2000年 | 102篇 |
1999年 | 92篇 |
1998年 | 114篇 |
1997年 | 105篇 |
1996年 | 113篇 |
1995年 | 86篇 |
1994年 | 63篇 |
1993年 | 84篇 |
1992年 | 54篇 |
1991年 | 64篇 |
1990年 | 84篇 |
1989年 | 112篇 |
1988年 | 76篇 |
1987年 | 85篇 |
1986年 | 102篇 |
1985年 | 109篇 |
1984年 | 64篇 |
1983年 | 65篇 |
1982年 | 44篇 |
1981年 | 40篇 |
1980年 | 54篇 |
1979年 | 31篇 |
1978年 | 27篇 |
1977年 | 40篇 |
1976年 | 26篇 |
1975年 | 31篇 |
1974年 | 20篇 |
1973年 | 24篇 |
1971年 | 14篇 |
排序方式: 共有4595条查询结果,搜索用时 15 毫秒
1.
Isolated patellofemoral arthritis is an increasingly recognized entity, and is usually associated with previous patellofemoral dysplasia or instability. Patellofemoral arthroplasty (PFA) has evolved significantly in recent years, both in terms of implant design and importantly in the understanding of appropriate patient selection. This review outlines the indications and investigations for PFA, provides a brief history of the development of contemporary implants, and presents the clinical outcomes for the prostheses most commonly used in the UK. In addition, it provides a detailed surgical technique for implantation of an onlay implant, with tips on how to optimize patellofemoral biomechanics and thus achieve a consistently good outcome. 相似文献
2.
Robert J. Motzer MD Bernard Escudier MD Saby George MD Hans J. Hammers MD PhD Sandhya Srinivas MD Scott S. Tykodi MD PhD Jeffrey A. Sosman MD Elizabeth R. Plimack MD Giuseppe Procopio MD David F. McDermott MD Daniel Castellano MD Toni K. Choueiri MD Frede Donskov MD PhD Howard Gurney MD Stéphane Oudard MD Martin Richardet MD PhD Katriina Peltola MD PhD Ajjai S. Alva MD Michael Carducci MD John Wagstaff MD Christine Chevreau MD Satoshi Fukasawa MD Yoshihiko Tomita MD PhD Thomas C. Gauler MD Christian K. Kollmannsberger MD Fabio A. Schutz PhD James Larkin MD PhD David Cella PhD M. Brent McHenry PhD Shruti Shally Saggi BEng Nizar M. Tannir MD 《Cancer》2020,126(18):4156-4167
3.
4.
Steven R. Jensen M.D. Dawn R. Voegeli John C. McDermott Andrew B. Crummy 《Cardiovascular and interventional radiology》1986,9(4):202-204
Eight lymphatic fluid collections were drained percutaneously. There were no immediate or late complications. Seven patients
had follow-up; 1 required surgical drainage of a residual or recurrent lymphocele, and another had reaccumulated fluid in
a lymphocele which was detected on autopsy. The remaining lymphatic collections responded to percutaneous drainage. Percutaneous
drainage is safe and can be an effective tool in the management of lymphatic collections. 相似文献
5.
RA O. Hempel 《Notfall & Rettungsmedizin》2007,10(5):367-371
Legal uncertainties for emergency vehicle drivers can be avoided when fundamental rules are established. In particular, differentiation of special rights and rights of way is essential. Inherent in both is the urgency necessary to save human lives. The right of way signaled by flashing blue lights and siren does not however justify traffic violations but signifies rather a request to other traffic participants. In contrast, special rights require no announcement and constitute a justifiable reason for traffic violations. Even so they do not allow that other traffic participants be endangered or harmed. Adherence to these basic principles can prevent legal misinterpretations as well as rigid adoption of inflexible standards of behavior. 相似文献
6.
RA Mag. Dr. C. Gepart 《Notfall & Rettungsmedizin》2007,10(4):289-292
Austria’s new Living Wills Act (Patientenverfügungsgesetz, or PatVG) that came into effect on 1st of June 2006, is the first law in Austria to regulate the controversial issue of living wills. The PatVG provides for a right to refuse future medical treatment by making an advance directive in the form of a living will that is either binding or “to be taken into consideration”. However, the establishment of a binding living will is governed by strict criteria as regards form and content, and both a medical doctor and a legal expert must be involved. Compliance with a living will is not allowed where there is a legal obligation to give medical treatment. There is also a legal obligation to give medical treatment in emergency situations where the time involved in looking for a living will could seriously endanger the health or the life of a patient. 相似文献
7.
F T McDermott G Whelan D J St John G L Barnes R Elliott R Herrmann G T Schmidt R A Smallwood 《The Medical journal of Australia》1987,146(10):525, 528-525, 529
Information on the relative incidence of Crohn's disease and ulcerative colitis was obtained by a prospective investigation at six Melbourne teaching hospitals. One hundred and eleven patients who presented with chronic inflammatory bowel diseases between 1980-1981 were admitted to the study. Forty (36%) patients were diagnosed as having Crohn's disease and 63 (57%) patients as having ulcerative colitis. The type of chronic inflammatory bowel disease could not be determined in eight (7%) patients. These findings suggest that the relative frequency of Crohn's disease and ulcerative colitis in Melbourne hospitals is within the range that is reported for northern Europe and the United States. 相似文献
8.
Ohne Zusammenfassung 相似文献
9.
M.B. McDermott A.C. Lind E.F. Marley L.P. Dehner 《Pediatric and developmental pathology》1998,1(4):300-308
Deep granuloma annulare (DGA) is one of several lesions of skin and superficial soft tissues whose histologic character is
a palisading granuloma with a small central focus of necrosis or necrobiosis. Unlike the other palisading necrobiotic lesions,
DGA has a predilection for children in the first 5 to 6 years of life. A painless subcutaneous nodule(s) in the lower anterior
tibial region or foot and the scalp, typically in the occiput, was the most common presenting feature in this study of 35
cases. Additional or recurrent lesions were reported in approximately 70% of cases with clinical follow-up. All lesions showed
the presence of necrobiosis; however, one of the characteristic features was the multinodular character of the predominantly
mononuclear cellular aggregates. The presence of vascular spaces at the periphery of the nodular profiles served as a clue
to the diagnosis of DGA. The palisading arrangement of the mononuclear cells was evident only in those foci with central necrobiosis.
A histiocytic disorder or fibrohistiocytic process was a common consideration in the differential diagnosis, especially in
those cases with less apparent foci of necrosis. Palisading histiocytes with prominent eosinophilic cytoplasm and some nuclear
atypism were problematic with regard to possible epithelioid sarcoma. Our study failed to identify any underlying or predisposing
factors in the development of DGA. Despite the fact that DGA is a well-documented lesion in children, it occurs sufficiently
infrequently that it is often not considered clinically when it presents as a subcutaneous mass or masses in a child. Its
recognition by the pathologist is especially important as the occurrence of additional lesions in a high proportion of children
can be anticipated without undue concern.
Received June 16, 1997; accepted October 28, 1997. 相似文献
10.
Both cyproterone acetate (CPA) and the gonadotrophin-releasing hormone
agonist (GnRHa) have been shown to be effective for the treatment of
hirsutism. We wished to compare the effectiveness of CPA in two standard
doses with GnRHa and add-back therapy and to compare the length of
remission after these treatments. A total of 60 hirsute hyperandrogenic
women was assigned to the following treatment groups: CPA 2 mg with 35
microg of ethinylestradiol for 21 days each month (Diane group), CPA 50 mg,
days 5-15, and ethinylestradiol 50 microg, days 5-25, each month (CPA
group) or Decapeptyl 3.75 mg i.m. every 28 days with the addition of
conjugated oestrogen 0.625 mg, days 1-21, and medroxyprogesterone acetate
10 mg, days 12-21 (GnRHa group). Hirsutism was graded by the
Ferriman-Gallwey-Lorenzo (FGL) index and anagen hair shaft diameters and
serum luteinizing hormone (LH) and testosterone were assessed before and
every 3 months during and after treatment. All women were treated for 1
year with 1 year follow-up. At baseline hirsutism and endocrine patterns
were similar in all groups. After one year of treatment, hirsutism
decreased in all groups but the changes were greater (P <0.05) in the
CPA and GnRHa groups than in the Diane group. Serum LH and testosterone
were lowest in the GnRHa group. After withdrawal, hirsutism increased
rapidly in the Diane and CPA groups and after 6 months, FGL scores and hair
shaft diameters were similar to pretreatment values. In the GnRHa group,
hirsutism increased more gradually and after 1 year of withdrawal, FGL
scores and hair diameters were significantly (P <0.05) less than
pretreatment values. Serum LH and testosterone increased rapidly in all
three groups reaching pretreatment values by 6 months. These data suggest
equal efficacy of the GnRHa and the high dose CPA regimen for the treatment
of hirsutism in hyperandrogenic women. GnRHa with add-back treatment
appears to result in a longer remission of hirsutism in comparison with
CPA.
相似文献